Ascendis Pharma A/S (ASND)
131.53
-2.51 (-1.87%)
At close: Jan 14, 2025, 3:59 PM
134.00
1.88%
Pre-market Jan 15, 2025, 04:10 AM EST
undefined% (undefined)
| Bid | 113.98 |
| Market Cap | 7.86B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -7.64 |
| PE Ratio (ttm) | -17.22 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 210.51 |
| Volume | 364,663 |
| Avg. Volume (20D) | 417,762 |
| Open | 135.30 |
| Previous Close | 134.04 |
| Day's Range | 131.05 - 137.54 |
| 52-Week Range | 111.09 - 161.00 |
| Beta | undefined |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 28, 2015
Employees 879
Stock Exchange NASDAQ
Ticker Symbol ASND
Website https://ascendispharma.com
Analyst Forecast
According to 14 analyst ratings, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $191, which is an increase of 45.22% from the latest price.
Buy 92.86%
Hold 7.14%
Sell 0.00%
Next Earnings Release
Ascendis Pharma A/S is scheduled to release its earnings on Feb 5, 2025,
during market hours.
Analysts project revenue of $97.53M, reflecting a -34.2% YoY shrinking and earnings per share of -1.29, making a -22.29% decrease YoY.
Analysts project revenue of $97.53M, reflecting a -34.2% YoY shrinking and earnings per share of -1.29, making a -22.29% decrease YoY.
2 months ago ·
Source
+1.79%
Acendis Pharma shares are trading higher after Sti...
Unlock content with
Pro Subscription
2 months ago ·
Source
-1.39%
Ascendis Pharma shares are trading lower. The company reported Q3 financial results.
